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We assessed the impact of HIV-1 on malaria in the
sub-Saharan African population. Relative risks for malaria
in HIV-infected persons, derived from literature review,
were applied to the HIV-infected population in each coun-
try, by age group, stratum of CD4 cell count, and urban ver-
sus rural residence. Distributions of CD4 counts among
HIV-infected persons were modeled assuming a linear
decline in CD4 after seroconversion. Averaged across 41
countries, the impact of HIV-1 was limited (although quan-
titatively uncertain) because of the different geographic dis-
tributions and contrasting age patterns of the 2 diseases.
However, in Botswana, Zimbabwe, Swaziland, South
Africa, and Namibia, the incidence of clinical malaria
increased by <28% (95% confidence interval [CI] 14%–
47%) and death increased by <114% (95% CI 37%–188%).
These effects were due to high HIV-1 prevalence in rural
areas and the locally unstable nature of malaria transmis-
sion that results in a high proportion of adult cases. 
H
IV-1 infection increases the risk and severity of malar-
ia (1,2). In African settings of both high- and low-
intensity (epidemic, unstable, or strongly seasonal) malaria
transmission, increases in the severity and case fatality of
malaria have been observed in all age groups (3–8). In areas
of high-intensity transmission, HIV-1 also increases the
incidence of clinical malaria among adults (9). 
The population-level impact depends on HIV preva-
lence, the age distribution of both infections (which for
malaria is determined by the transmission intensity), and
their geographic overlap. Local distributions of CD4 cell
counts and clinical stages of HIV-infected patients are also
important because the effects of HIV multiply with
increasing immunosuppression (9,10). 
The HIV-1 epidemic in Africa has matured over the past
25 years and may now be reaching a peak (11). From the
1980s to the 1990s, malaria death and disease increased,
especially among children in rural, malaria-endemic parts
of East and West Africa (12), and in populations at risk for
unstable malaria in South Africa (13–15). Chloroquine
resistance (16), breakdown of vector-control operations
(17), and HIV-1 may all have contributed to these trends
(3,4,13). We assessed the number of additional malaria
cases and deaths caused by HIV-1 in sub-Saharan Africa
by calculating the impact of HIV-1 separately for urban
and rural populations, areas of high- and low-intensity
malaria transmission, and different age groups in each
country.
Methods
Malaria Incidence in the Absence of HIV-1 
In the absence of reliable data from routine health infor-
mation systems, the incidence of uncomplicated and
severe clinical malaria episodes, collectively referred to
here as “malaria incidence,” was calculated from estimates
of incidence rates (Table 1) and national populations at risk
for malaria in 2004 (Table 2), by using the 1998 map of cli-
matic suitability for malaria transmission (18). The climate
suitability index was used to indicate high- (>0.75) or low-
intensity transmission (>0 and <0.75) (19). For high-inten-
sity transmission areas, average incidence of malarial
fevers in the absence of HIV was estimated at 1.4 per per-
son per year among children <5 years of age, 0.59 per per-
son per year in those 5–14 years of age, and 0.11 per
person per year in those >15 years of age (19). In areas of
low transmission, incidence among those <5 years of age
was estimated at 0.182 per person per year (19). Because
immunity against clinical malaria increases slowly with
age in areas of low-intensity transmission, the incidence
rate among 5- to 14-year-olds and those >15 years were
considered to be the same as that in young children and
half that rate, respectively (19). 
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Zimbabwe, only areas with a climate suitability index
>0.75 on the Malaria Risk in Africa map were considered
to have transmission of unstable nature because vector
control has been successful in some places (19). The aver-
age incidence in malarious areas in these countries has
been estimated as 0.0294 per person per year (19). Age-
specific incidence rates from clinic data have only been
reported from Zimbabwe. We, therefore, applied the age
distribution from areas of low transmission in Central
Africa (see above and Table 1), which gave proportions of
cases among children <5 years of age from 16% to 22%, in
agreement with the 21% among reported cases in
Zimbabwe.
We assumed that the urban-rural ratio in malaria inci-
dence rates was 0.50, a conservative estimate based on 3-
to 24-fold lower entomologic infection rates in periurban
and urban areas compared to rural areas (20) and the
approximately linear increase in infection rates with
increasing entomologic infection rates up to a certain satu-
ration point (29). Proportions of urban persons were
assumed to be the same in areas of high, low, and unstable
transmission, because the Malaria Risk in Africa risk clas-
sification (18) did not incorporate small-scale variation
due to urban environment. Urban and rural populations
were based on countries’ definitions (30), without stan-
dardization between countries. 
Effects of HIV-1 on Malaria Incidence
The best evidence for associations between HIV-1 and
clinical malaria comes from 2 longitudinal studies in
Uganda, where malaria transmission is of high intensity. A
community-based study in rural Masaka found odds ratios
of clinical malaria among HIV-positive adults compared to
HIV-negative adults, of 1.2, 3.4, and 6.0 for CD4 counts
>500/µL, 200–499/µL, and <200/µL, respectively (p =
0.0002) (9). As in earlier studies, malaria incidence was
defined as any acute fever concurrent with malaria para-
sitemia, without excluding alternative causes of the fever
through further laboratory tests. Because malaria infection
may occur without symptoms, in particular among adults
in settings of high-intensity transmission, and because
HIV-infected people often have acute nonmalarial fevers
(10), the effect of HIV may have been overestimated. 
The second study in Uganda, on HIV-positive persons
only, excluded alternative causes of acute febrile illness,
such as bacteremia (10). Malaria incidence for CD4 counts
>500/µL, 200–499/µL, and <200/µL was 57, 93, and 140
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fever episodes with high parasitemia, 22, 53, and 90 per
1,000 person-years (10). We, therefore, assume that HIV-1
increases malaria incidence in adults by 1.2, 3, and 5 times
for the above CD4 categories.
No community-level data are available for children,
but 4 hospital-based cohorts in settings of high malaria
transmission were studied in the late 1980s (6,8,27,31). In
a birth cohort in Kinshasa, HIV-1 infection at any stage
and clinically diagnosed AIDS increased malaria inci-
dence by 1.2- and 2-fold, respectively, but the increases
were not significant (8). A birth cohort in Blantyre,
Malawi, found no HIV-related increase in the incidence of
parasitemia (31). In Kampala, perinatally HIV-infected
children with AIDS experienced notably fewer malaria
episodes than HIV-uninfected children (6), which the
authors attributed to the increased use of chloroquine
before hospitalization among the HIV-infected children.
In contrast, among children in Kinshasa from 1986 to
1988 who had received blood transfusions, those who
were HIV-infected experienced 1.4 times more clinical
malaria than those who were not (27). The effect of HIV-
1 on malaria incidence is likely less apparent in children
than in adults in high-transmission areas because young
children have a high incidence of symptomatic malaria
anyway (19). However, the observations may be con-
founded by prehospital use of antimalarial drugs or the
shorter follow-up times and younger ages of HIV-infected
children. We assumed that HIV-1 does not increase malar-
ia incidence in children <5 years of age in high-transmis-
sion areas. Few data from areas of low-level and unstable
malaria transmission in Africa exist and we assumed that
HIV-1 increases malaria incidence equally in adults and
children by the risk ratios specified above for adults in
high-transmission areas.
The observed effect of HIV-1 on the incidence of clini-
cal malaria may in part be the result of an increased inci-
dence of recrudescences after failing antimalarial
treatment because HIV-1 lowers the efficacy of antimalar-
ial treatment (32,33). No published studies report specifi-
cally on the effect of HIV on malaria recrudescence. If
such an effect exists, however, it will have been accounted
for under the assumed overall effect of HIV on clinical
malaria, since none of the studies from which we derived
this assumed overall effect (6,8–10,27,31) adjusted malar-
ia incidence rates observed in HIV-positive and HIV-nega-
tive participants for differences between these groups in
treatment failure.
Malaria Mortality and Effect of HIV
Malaria mortality was derived from malaria incidence,
assuming fixed case-fatality rates. In high-transmission
areas, 0.3% of malaria episodes were assumed to be fatal
in adults and 0.8% in children (21). In areas of low-level
transmission, we assumed a fatality rate of 0.8% for all
ages (21). 
Studies on adults in areas of high malaria transmission
showed that HIV-1 infection increased case fatality among
hospitalized persons with severe malaria by 1.6- to 2.5-
fold (7,34,35), while the incidence of severe malaria, a pre-
cursor of fatal episodes, increased by 2.7-fold (36). In
children exposed to high transmission in Kinshasa, HIV-1
increased the rate of hospitalization for malaria by 6-fold
and malaria case fatality by 9.8-fold, although these effects
were not significant; among HIV-infected persons who did
not meet clinical criteria for AIDS, rates of hospitalization
or death due to malaria did not increase (8). In Kampala,
perinatally infected children were hospitalized for malaria
2.8 times more often than HIV-uninfected children (p =
0.001) (6). 
In areas of low intensity and unstable malaria transmis-
sion, malaria diagnosis is less problematic because of less
acquired immunity. Hospital-based studies in Zimbabwe in
1999 and Kwa-Zulu Natal, South Africa, in 2000, docu-
mented 6.9- and 8.8-fold increases in malaria case fatality
among HIV-infected adults relative to HIV-negative
patients (4,5). In Soweto, South Africa, a significant 1.7-
fold increase in the rate of severe malaria was observed
(37). For children living in areas of unstable malaria trans-
mission, a hospital-based study in Kwa-Zulu Natal found a
2.7-fold increase in severe malaria (p = 0.05) and a 3.6-
fold increase in fatality among severe cases (p = 0.1) asso-
ciated with HIV-1 (3).
These data collectively suggest that HIV-1 increases
malaria deaths by increasing the proportion of severe
cases, case fatality among them, and the failure rate of
antimalarial treatment (32,33). We conservatively assumed
that the malaria death rate is increased by 4 times, taking
into account the problem of attributing fevers to malaria.
Lacking further evidence, we applied this increase to all
age groups and malaria transmission intensities. One study
found that the effect of HIV-1 was greater for CD4
<200/µL (37), and we assumed that malaria death rate
increases with falling CD4 counts in the same way as
malaria incidence, giving relative death risks among HIV-
1–positive participants relative to HIV-1–negative ones of
2, 4, and 10 for CD4 >500 cells/µL, 200–499/µL, and
<200/µL. 
HIV-1 Prevalence
Estimates of national HIV-1 prevalence among adults
(>15 years of age), children <5 years of age, and children
5–14 years of age are available from the Joint United
Nations Programme on HIV/AIDS (UNAIDS) for 2003
(28). To evaluate impact separately for urban and rural
areas, which differ in malaria transmission intensity (20),
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from national household surveys or antenatal clinic sur-
veillance data (UNAIDS and [11]). 
CD4 Distributions among HIV-infected Persons
The distribution of CD4 counts among HIV-infected
persons follows from the pattern of CD4 decline after ini-
tial infection and the trend in HIV-1 prevalence over pre-
ceding years (online Appendix, available at
http://www.cdc.gov/ncidod/EID/vol11no09/05-
0337_app.htm). Data from a variety of populations not
receiving antiretroviral therapy suggest that CD4 decline is
approximately linear after infection with HIV-1 (26,38). In
African patients, CD4 declines from ≈825/µL, the median
value in HIV-uninfected adults (23–26,39), to a mean of
20/µL at death of AIDS (40). 
CD4 distributions among HIV-infected adults in coun-
tries with different HIV-1 epidemics were determined by
exploring 4 different epidemic patterns: 1) Uganda, where
adult prevalence fell from a peak of ≈13% in the early
1990s to an estimated 4.1% (2.8%–6.6%) in 2003; 2)
Ghana, where adult prevalence was relatively stable in
recent years at 3.1% (1.9%–5.0%) in 2003; 3) South
Africa, where the epidemic started only in the 1990s but
reached an estimated prevalence of 21.5% (18.5%–24.9%]
in 2003; and 4) Madagascar, where adult prevalence has
risen rapidly in recent years to an estimated 1.7%
(0.8%–2.7%) in 2003 (Figure 1) (28)]. In all 4 countries,
most HIV-1 patients had CD4 >500/µL at the start of the
epidemic (Figure 2). In Uganda, the prevalence of CD4
<500/µL rose rapidly until 1996, 6 years after the peak in
HIV-1 prevalence. In the other epidemics, the prevalence
of low CD4 rose more slowly, following their later stabi-
lization. At means of 430 to 660/µL for 1996, the modeled
CD4 counts are consistent with empiric data on HIV-
infected African adults, which found means of 400 to
630/µL (23,24,26) and medians of 325 to 660/µL
(9,23,24,26,39). Also, the modeled CD4 counts for South
Africa from 2000 to 2005 (Figure 2) were in agreement
with the observed distribution of 50%, 40%, and 10% with
CD4 >500/µL, 200–499/µL, and <200/µL, respectively, in
Soweto in 2002 (39). 
Despite their different epidemic curves, the modeled
CD4 distributions among HIV-1 patients were fairly simi-
lar for Uganda, Ghana, and South Africa in 2004:
44%–45% have CD4 >500/µL, 36%–41% have CD4
200–499/µL, and 15%–19% have CD4 <200/µL. We
assume similar CD4 distributions for all other countries in
which HIV prevalence has also stabilized. In Madagascar
only, where HIV prevalence still increases rapidly, CD4
counts are notably higher (Figure 2). We therefore applied
2 distributions: in Madagascar, 60% of HIV-infected adults
had CD4 >500/µL, 30% had CD4 200–499/µL, and 10%
CD4 <200/µL; for other countries, assumed proportions
were 44%, 39%, and 17%, respectively.
Results
HIV-1 increased malaria incidence by 0.20% to 28%
across countries (Table 2). The largest increases were in
Botswana, South Africa, Swaziland, Zimbabwe, and
Namibia, where HIV-1 prevalence is highest, especially in
rural areas, and malaria transmission most unstable. For
any given HIV-1 prevalence, HIV-1 impact was greatest in
countries with low-intensity or unstable malaria transmis-
sion, where relatively more malaria occurs in adults. For
example, impact was greater in Burundi than in Liberia,
where malaria transmission is higher, despite an HIV
prevalence of ≈6% in both countries. Outside southern
Africa, impact was relatively high in the Central African
Republic, with a comparatively high HIV-1 prevalence
rurally, and Kenya, with a high proportion of low-intensi-
ty malaria transmission. 
Across 41 countries, HIV-1 increased malaria incidence
by 1.3%. This relatively small impact is explained, first, by
the different geographic distributions of the 2 diseases.
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Figure 2. Modeled time trends in CD4 count distributions (per
microliter) among HIV-infected adults in selected African countries.
Madagascar: example of a rising HIV-1 epidemic at low grade;
Ghana: example of a stable epidemic at low grade; Uganda:
example of a high-grade epidemic that has declined and leveled
off; South Africa: example of a high-grade epidemic that recently
started leveling off.
Figure 1. Modeled time trends in HIV-1 prevalence (adults 15-49
years), based on UNAIDS estimates from sentinel surveillance
data in antenatal clinics (28).Malaria incidence rates are highest in West and Central
Africa, where HIV-1 prevalence is comparatively low
(Table 2). HIV-1 is most prevalent in southern Africa,
where malaria transmission is rarely stable and compara-
tively well controlled. Second, within countries, the impact
of HIV-1 was further limited because HIV-1 is more preva-
lent in cities (median urban/rural ratio 1.6, Table 2), where-
as malaria is more prevalent rurally (assumed urban/rural
ratio 0.5). Third, HIV-1 mainly affects adults; whereas in
countries of high malaria transmission, malaria has the
greatest impact on young children. 
HIV-1 increased malaria deaths by 0.65% to 114%
across countries (Table 2). As for malaria incidence, the
largest increases were in southern Africa (Figure 3), and
the ranking among countries was very similar to the rank-
ing by impact on malaria incidence. On a continental scale,
HIV-1 increased malaria deaths by 4.9%. The impact on
malaria deaths was greater than that on malaria incidence
for 2 reasons. First, in the individual patient, HIV-1
increases death risk more than incidence (Table 1).
Second, the impact of HIV-1 on death was compounded by
its impact on incidence rates. 
Against our baseline of ≈228 million malaria cases and
≈1.3 million malaria deaths among all ages in sub-Saharan
Africa, these increases would correspond to an additional
3 million malaria cases and 65,000 malaria deaths annual-
ly due to HIV-1, or to ≈3% of the estimated 2.3 million
HIV/AIDS deaths in sub-Saharan Africa in 2004 (28).
However, the assumed baseline malaria incidence and
death rates were cruder than we would have liked and do
not take into account the impact of malaria control in the
different countries. We, therefore, focus on relative
increases in malaria due to HIV.
Alternative Scenarios
To assess the sensitivity of results to assumptions made,
we recalculated the impact of HIV-1 for several alternative
scenarios (Table 3). Estimated impact increased or
decreased considerably with larger or smaller assumed rel-
ative risks at the individual level. Most critical, however,
were the assumed age patterns in malaria incidence and
case fatality. The smaller the decline with age in malaria
incidence and fatality rates, the greater the impact of HIV-
1 would be (<12.5% increase in malaria deaths and 4.4%
increase in malaria incidence, Table 3) because of the con-
centration of HIV-1 in adults. 
Estimates were relatively insensitive to whether the
effect of HIV-1 on malaria incidence applied also to chil-
dren in high-transmission areas, as a recent study in
Uganda suggested (41). Alternative assumptions concern-
ing the range over which CD4 counts decline during HIV
infection also made little difference. Abandoning the
assumption that malaria occurs more frequently in rural
than in urban areas resulted in only a slight increase in
HIV-1 impact because the countries with highest HIV-1
prevalence and Nigeria, which has most malaria cases, had
similar HIV-1 prevalence in cities and rural areas (Table
2). Finally, estimated impacts were moderately sensitive to
uncertainties in national HIV prevalence for adults but not
to uncertainties in HIV prevalence for children. 
Combining the ranges of estimates from these scenarios
into 1 multivariate analysis, with the Monte Carlo tech-
nique and assuming triangular distributions for all param-
eters, overall 95% confidence intervals (CIs) on the
continentwide estimates would be 0.6%–7.9% (best esti-
mate  ≈1.3%) for clinical malaria incidence, and
3.1%–17.1% (best estimate ≈4.9%) for malaria deaths. For
Botswana, the country with the largest estimated HIV
impact, 95% CI would be 14%–47% (best estimate ≈28%)
for malaria incidence and 37%–188% (best estimate
114%) for malaria deaths.
Discussion
Across 41 countries in sub-Saharan Africa, the HIV-1
epidemic may have increased the incidence of clinical
malaria by 1.3% (95% CI 0.6%–7.9%) and malaria deaths
by 4.9% (95% CI 3.1%–17.1%) in 2004. Continentwide
impact was limited by the different geographic distribu-
tions of the 2 diseases and their different age patterns. 
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Figure 3. Estimated proportional increases in malaria deaths due
to HIV-1 in sub-Saharan African countries in 2004, for all ages
combined.For southern Africa, estimated proportional increases
were <28% (95% CI 14%–47%) for malaria incidence and
<114% (95% CI 37%–188%) for malaria deaths. An
impact of HIV-1 of this magnitude may have contributed
to observed increases of malaria in the 1990s in areas of
unstable transmission, including Kwa-Zulu Natal (13,14)
and northern Zambia (15). Outside southern Africa, how-
ever, HIV-1 is unlikely to be a major contributor to rises in
malaria, and where this appears to be so, a more plausible
explanation may be overdiagnosis of fevers as malaria in
RESEARCH
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HIV-1 patients. Such over-diagnosis may occur uninten-
tionally in settings where malaria is diagnosed without
parasitologic confirmation because of the increased fre-
quency of acute fevers in HIV-1 patients (10). Intentional
misdiagnosis could also occur, if doctors are reluctant to
diagnose illness as HIV-related for fear of social stigma. 
These estimates have several limitations. First, the
magnitude of effects of HIV-1 on malaria incidence and
death risk in individual patients is critical (Table 3) but
uncertain because of diagnostic problems in settings of
high malaria transmission and a lack of population-based
data from areas of low intensity and unstable transmission. 
Second, results are sensitive to age patterns in malaria
(Table 3), which are not well known. The sharp contrast in
estimated impact of HIV-1 between the 5 southern African
countries and the remainder of Africa depends on the
assumption that malaria declines more slowly with age in
South Africa, where all malaria is assumed to be unstable.
In practice, the shift from unstable to stable malaria trans-
mission, i.e., from clinical effects in all age groups to a
predominance in young children, is more gradual; thus,
effects of HIV on malaria in Zimbabwe and Zambia, for
example, may be more similar than we estimated. The esti-
mation method developed here could, nevertheless, be
applied to more refined age-specific estimates of malaria
incidence and death.
Finally, subnational heterogeneity in malaria or HIV,
apart from urban/rural differences, was not considered, and
this fact may have biased the estimation for countries
where either or both diseases are heterogeneously distrib-
uted, such as Kenya, Ethiopia, Tanzania, and South Africa
(42). For example, in South Africa, both malaria and HIV-
1 are concentrated in Kwa-Zulu Natal, so that their inter-
action may be greater than our estimate.
The impact of HIV-1 that we have estimated only per-
tains to malaria cases and deaths and does not include
effects on anemia or adverse birth outcomes attributable to
concurrent malaria and HIV-1 in pregnant women. In areas
of high-intensity transmission, such as in Kenya and
Malawi, the latter effects might be more important than
malaria cases and deaths per se. Also, our analysis did not
cover the effect of HIV-1 on demand for antimalarial
drugs. In most of rural Africa, antimalarial drugs are pre-
sumptively prescribed to treat any fever without an obvi-
ous nonmalarial cause. Recurrent fevers in HIV-1 patients
may, therefore, cause considerable overuse of antimalarial
drugs, increasing not only costs but also the risk for drug
resistance. The HIV-1 epidemic thus underlines the need to
improve capacity for laboratory diagnosis of febrile dis-
ease in Africa.
To limit the impact of HIV-1 on malaria, HIV-infected
persons, in addition to young children and pregnant
women, may form a target group for provision of insecti-
cide-treated mosquito nets (2). In areas of low intensity 
and unstable transmission, HIV may be a reason for inten-
sifying or resuming indoor residual spraying to control
malaria vectors. For HIV-infected persons who are prone
to treatment failure with conventional antimalarial drugs
(27,32,33,43), effective combination therapy is of utmost
importance. 
Highly active antiretroviral combination therapy has
great potential to reduce HIV-related malaria (44).
Cotrimoxazole prophylaxis, recommended for adults and
children living with HIV in Africa (45), is also effective in
reducing clinical malaria, independent of baseline CD4
(41,46,47). Combined HIV and malaria interventions
might best be delivered at peripheral health centers,
including antenatal clinics (2). 
HIV-1 appears to have increased the impact of malaria
disease and death in South Africa compared to the 1980s,
although data do not allow a precise quantification of this
effect. In areas of high HIV and low-intensity or unstable
malaria, continued vigilance and intensified malaria con-
trol are indicated. In HIV-infected adults, pregnant women,
and children, malaria is among the simplest opportunistic
infections to prevent and treat.
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